Key Highlights
- The chief executive of Hims & Hers defended the telehealth company against a Federal Trade Commission lawsuit over its data sharing and subscription practices
- The FTC lawsuit, filed alongside Los Angeles County and Utah, accused the company of sharing user health data with advertisers and making subscriptions hard to cancel
- The CEO said the company's earlier sale of compounded GLP-1 drugs helped bring prices down for the popular obesity treatments
- Hims & Hers is developing its own AI agents in-house, moving away from third-party AI tools, according to the CEO
CEO Pushes Back on FTC Allegations
Hims & Hers (NYSE:HIMS) chief executive defended the telehealth company amid a Federal Trade Commission lawsuit over its data sharing practices, saying in a wide-ranging interview that the allegations stem from a misunderstanding of how the company is transforming healthcare. He said it takes time for people to understand how a traditional system like healthcare is being rebuilt in a digital ecosystem, adding that the company has worked with the FTC for years to explain its approach and believes the agency ultimately wanted more of a headline than a genuine agreement.
In July, the FTC, along with Los Angeles County and the state of Utah, filed a lawsuit against Hims & Hers accusing the company of sharing user health information with advertisers, charging for prescriptions before customers had spoken with a healthcare provider, and making it difficult for customers to cancel subscriptions. The CEO defended the company's Business model, saying it was built around increasing access to care and that the company is willing to act as a disruptor when it believes doing so serves people's best interests.
Transition From Compounded to Branded GLP-1 Drugs
The CEO also addressed the company's transition from compounded to branded GLP-1 weight loss drugs. When popular obesity treatments were in shortage in prior years, the company was able to legally sell compounded, or copycat, versions at a discount. After Supply recovered, a major pharmaceutical company sued Hims & Hers for Patent infringement, later dropping the suit in March after the telehealth company agreed to sell the drugmaker's branded products on its platform.
That agreement came as the drugmaker and its main rival were cutting prices on their GLP-1 treatments for patients paying out of pocket. The CEO said the company will always apply pressure to the healthcare system when it believes doing so benefits consumers, adding that selling compounded GLP-1 drugs during the shortage showed both consumers and drug companies that the medications could be made available at a price more people could afford. He said he ultimately expects prices for cash-paying patients to fall to between $40 and $50 per month, down from roughly $150 to $200 currently, depending on the form of the medication.
Company Building Its Own AI Tools In-House
The CEO also said he believes artificial intelligence will dramatically transform healthcare, and that the company is increasing its Investment to become what he described as AI native. He said Hims & Hers is moving away from using third-party AI agents and building its systems in-house, arguing that foundational AI models are not especially valuable on their own without a closed-loop proprietary data set.
He said the closed-loop data the company holds within its own healthcare platform represents the real asset, describing that as his honest assessment of where value lies in applying AI to healthcare going forward.






Please wait processing your request...